has knowledgeable contact person
Protocols  >  Clinical protocol  >  Active immunotherapy in adv...

Active immunotherapy in advanced melanoma patients

Clinical protocol

The vaccine is composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).

Protocol Steps:
  • Electroporation Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine
  • Vaccination of patients Advanced melanoma patients are vaccinated with the DC vaccine.
Active immunotherapy in advanced melanoma patients Graph


created over 8 years ago (2 March 2009)    last modified over 5 years ago (28 September 2011)   [ RDF Rdf ]   [ RelFinder Relfinder ]